Interferon therapy and its association with depressive disorders - A review

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Interferons (IFNs) are vital for innate immunity against viruses, with additional antimicrobial, antitumor, and immunomodulatory roles.
• Type I IFNs, specifically IFN-α, are used to treat Hepatitis C but can induce neuropsychiatric disorders.
• IFN-α triggers inflammation via cytokines, indoleamine 2,3-dioxygenase (IDO), and oxidative stress, impacting behavior.

Purpose of the Study:

• To review the types, pharmacology, and clinical uses of IFNs.
• To focus on the implications of IFN-α treatment on depression and associated neurological mechanisms.

Main Methods:

• Literature review of IFNs, their clinical applications, and side effects.
• Analysis of the molecular pathways linking IFN-α to neuropsychiatric disorders, including oxidative stress and limbic system function.

Main Results:

• IFN-α treatment is associated with neuropsychological side effects, including depression.
• Mechanisms involve increased inflammation, oxidative stress (ROS), and potential damage to the hippocampus and limbic system.
• Severity of immune response correlates with behavioral changes in humans and animal models.

Conclusions:

• IFN-α's therapeutic benefits are counterbalanced by significant neuropsychiatric risks, particularly depression.
• Understanding these risks is crucial for patient management and treatment adherence.
• Proper management strategies can mitigate adverse effects, improving patient outcomes and treatment completion.